-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $106

Benzinga·08/12/2026 15:42:46
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $104 to $106.